Bristol-Myers Squibb Co (BMY) saw downtrend of -2.82% in the recent trading with $46.2 being its most recent. The current price level -27.05% lower than the highest price of $63.33 marked by the stock while trading over the past 52-weeks, whereas it is 7.54% higher than the lowest price of $42.96 the company dropped to over past 52-weeks. The latest news story on BMY appeared in (Zacks) under the title “Pfizer’s Late-Stage Pipeline Fuels Long-Term Growth Prospects”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 14 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.66 for the stock.
Bristol-Myers Squibb Co Earnings – What Happened With BMY
Coming around sales and income figures on BMY Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Bristol-Myers Squibb Co (BMY) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 19.98% for net revenue.
BMY – Bristol-Myers Squibb Co Stock Earnings Estimates
The perspective of Bristol-Myers Squibb Co (NYSE:BMY)’s current quarter earnings identifies that analysts are in consensus over the estimate of 1.5 for stock’s EPS in the current quarter. Bristol-Myers Squibb Co (BMY) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 19.98% for net revenue. Company’s EPS for the last quarter was 1.8.
Bristol-Myers Squibb Co – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 2.04 billion. BMY does have institutional investors; and they hold 82.25% of the stock.
As on 2024-06-30, VANGUARD GROUP INC was the top most holder in Bristol-Myers Squibb Co (NYSE:BMY) with an ownership of 186.57 million shares of the company or 9.2043 of the stake worth $7.75 billion. The filing also reveals BLACKROCK INC. as the second largest holder in the company with a control over 7.8273 of the outstanding shares. Its stake is worth $6.59 billion for having 158.66 million shares in hand.
STATE STREET CORP also came holding a key position in the company during the recent quarter and it now holds 4.5114 of the outstanding shares. With this there are now 2974.0 institutions which have possession in BMY’s shares.
Key Metrics for BMY
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Bristol-Myers Squibb Co has a debt to equity ratio of 2.92.
